Generic APIs
 Generic Products
 cGMP Manufacturing Facilities
 cGMP Production Capabilities
 cGMP Analytical Capabilities
 Regulatory Affairs
 Service and Partnership
 
 peptide and neuropeptide  WHAT'S NEW
 peptide and neuropeptide  ONLINE CATALOG
 peptide and neuropeptide  CUSTOM SYNTHESIS
 peptide and neuropeptide  ANALYTICAL DATA SHEET (ADS)
 peptide and neuropeptide  SERVICES
 peptide and neuropeptide  TECHNICAL LIBRARY
 peptide and neuropeptide  DOCUMENTS
 peptide and neuropeptide  SITEMAP
 peptide and neuropeptide  JOBS
 peptide and neuropeptide  CONTACT
   BOOKMARK & SHARE
  © Bachem AG
cGMP Production Capabilities    
 
Process Development

It is highly advisable to first optimize the manufacturing process.This typically results in an economic way to manufacture the product in the quantity and quality desired by our client. Bachem has a team dedicated to such process development work.



Solution phase peptide synthesis

Over 25 large reactors (up to 1400 liters) are dedicated to the synthesis of amino acid derivatives and peptides in solution.



Solid phase peptide synthesis

Over 15 reactors (each at least 75 liters) are dedicated to the solid phase synthesis of peptides



Purification

Large scale counter current distribution, high performance liquid chromatography equipment and conventional chromatography (ion exchange, gel chromatography), are utilized to overcome bottlenecks in large scale purification. Such equipment forms the foundation that allows us to obtain up to 10 kg per lot of highly purified product.

Bachem is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of multiple kilograms of bulk peptide pharmaceuticals.